跳至主要内容
临床试验/NCT02145494
NCT02145494Unknown2 期

Stereotactic Prostate Augmented Radiotherapy With Cyberknife

Royal Marsden NHS Foundation Trust2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2013年6月最近更新:
适应症

试验速览

阶段
2 期
入组人数
20
试验地点
2
主要终点
Acute genitourinary(GU) toxicity

研究概览

简要总结

Giving a higher dose of radiation to the dominant tumour nodule within the prostate is hypothesized to improve tumour control. This trial will assess whether this technique, delivered in 5 treatments, can be delivered without increasing side effects.

详细描述

Aim To assess if a focal boost can be delivered to the dominant tumour nodule alongside 36.25 Gy in 5 fractions to the whole prostate gland.

Primary end-point: Acute toxicity (Radiation Therapy Oncology Group (RTOG), International prostate symptom score (IPSS))

Secondary end-points: Prostate specific antigen (PSA) nadir and 2-year biochemical control Late toxicity (IPSS, RTOG, International index of erectile function (IIEF-5)) Quality of life (EQ5D scale)

Inclusion criteria

  • Prostate cancer patients with any of the following:
  • PSA>20
  • Gleason grade 4+3 or higher
  • Stage T3a
  • Exclusion criteria
  • Nodal or metastatic disease
  • PSA>40
  • Stage T3b or higher

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
Male
接受健康志愿者

入选标准

  • Prostate cancer patients with any of the following:
  • PSA 20-40
  • Gleason grade 4+3 or higher
  • Stage T3a

排除标准

  • Nodal or metastatic disease
  • Stage T3b or higher

结局指标

主要结局

Acute genitourinary(GU) toxicity

时间窗: Maximal recorded toxicity within the acute toxicity period (up to 12 weeks)

RTOG scale acute GU toxicity will be measured at baseline, end of treatment, then 2,4 and 12 weeks post treatment. The maximal toxicity during follow up is the primary outcome measure.

次要结局

  • Acute gastrointestinal (GI) toxicity(Within 12 weeks of treatment completion)
  • Late GI and GU toxicity(From 12 weeks until study completion)
  • Patient reported outcomes i.e. IPSS, IIEF-5 and EQ5-D(Baseline, 12 weeks, 12 months and 6 monthly to 5 years)
  • Biochemical relapse-free survival(Measured at 12 weeks after completion of treatment and 3-6 monthly to 5 years thereafter)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验